Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Müller

Showing results (71-80 of 101) with videos related to

Pageof 11
Sort By:
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Leukemia|July 31, 2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueA Hochhaus, M C Müller, J Radich, et al.
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 4, 1999
Predominance of CCR5-dependent HIV-1 subtype E isolates in CambodiaE Menu, J M Reynes, M C Müller-Trutwin, et al.
Leukemia|September 16, 2015
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinibK Wenn, L Tomala, S Wilop, et al.
Leukemia|October 26, 2002
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyA Hochhaus, S Kreil, A S Corbin, et al.
Theriogenology|June 12, 2016
Supplemented base medium containing Amburana cearensis associated with FSH improves in vitro development of isolated goat preantral folliclesB B Gouveia, T J S Macedo, J M S Santos, et al.
AIDS Research and Human Retroviruses|June 27, 1998
Phylogenetic analysis of SIV and STLV type I in mandrills (Mandrillus sphinx): indications that intracolony transmissions are predominantly the result of male-to-male aggressive contactsE Nerrienet, X Amouretti, M C Müller-Trutwin, et al.
AIDS Research and Human Retroviruses|May 1, 1996
HIV type 1 Thai subtype E is predominant in South VietnamE Menu, T X Truong, M E Lafon, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Pageof 11

Showing results (71-80 of 101) with videos related to

Sort By:
Pageof 11
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Leukemia|July 31, 2009
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueA Hochhaus, M C Müller, J Radich, et al.
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|May 4, 1999
Predominance of CCR5-dependent HIV-1 subtype E isolates in CambodiaE Menu, J M Reynes, M C Müller-Trutwin, et al.
Leukemia|September 16, 2015
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinibK Wenn, L Tomala, S Wilop, et al.
Leukemia|October 26, 2002
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyA Hochhaus, S Kreil, A S Corbin, et al.
Theriogenology|June 12, 2016
Supplemented base medium containing Amburana cearensis associated with FSH improves in vitro development of isolated goat preantral folliclesB B Gouveia, T J S Macedo, J M S Santos, et al.
AIDS Research and Human Retroviruses|June 27, 1998
Phylogenetic analysis of SIV and STLV type I in mandrills (Mandrillus sphinx): indications that intracolony transmissions are predominantly the result of male-to-male aggressive contactsE Nerrienet, X Amouretti, M C Müller-Trutwin, et al.
AIDS Research and Human Retroviruses|May 1, 1996
HIV type 1 Thai subtype E is predominant in South VietnamE Menu, T X Truong, M E Lafon, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Pageof 11